Sperm on Lockdown

In a proof-of-principle study, genetic deletion of two genes renders male mice infertile by preventing sperm transport through the vas deferens.

Written byAbby Olena, PhD
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

EUREKALERT, UNIVERSITY OF MONTREAL AND MAISONNEUVE-ROSEMONT HOSPITAL RESEARCH CENTERThe many barriers to the development of male contraception include potential effects on sex drive, irreversibility, and the sheer magnitude of sperm production—the human testes produce around 1,000 sperm every minute. Now, Australian researchers have shown that male mice lacking both the P2X1-purinoceptor and α1A-adrenoceptor are infertile, but behave normally and can father offspring by in vitro fertilization. Their work was published in Proceedings of the National Academy of Sciences this week (December 2).

Both the P2X1-purinoceptor, which is a ligand-gated ion channel, and α1A-adrenoceptor, which is a G protein-coupled receptor, are activated to cause contractions of the smooth muscle that lines the vas deferens, which in turn causes sperm to be pumped out during ejaculation. The researchers generated double knockout mice for P2X1-purinoceptor and α1A-adrenoceptor. While these male mice engaged in normal sexual behavior, they did not father offspring. The scientists demonstrated that the contractility of the vas deferens was severely compromised in the double knockout mice, but their sperm could be used to fertilize eggs in vitro, leading to live offspring. The findings suggested that if infertility could be induced by pharmacological inhibition of these receptors, it might be reversible.

“The sperm stay in the storage site ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies